



NDA 212994

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Commave Therapeutics SA
c/o Corium, LLC
Attention: Manisha Amin, PharmD, RPh
Authorized U.S. Agent
55 Cambridge Parkaway, Suite 401
Cambridge, Massachusetts 02142

Dear Dr. Amin:

Please refer to your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Azstarys (serdexmethylphenidate chloride and dexmethylphenidate hydrochloride) capsules, which was approved on March 2, 2021.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for the following PMR which was deferred until the date listed:

PMR 3980-3: Deferred until November 29, 2024.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **“DEFERRAL EXTENSION REQUESTED”** in your response.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a **“RESPONSE TO PREA NON-COMPLIANCE LETTER.”** To facilitate our review, submit this information to your NDA with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, please contact Ann Sohn, PharmD, Senior Regulatory Project Manager, at 301-796-2232 or ann.sohn@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tiffany R. Farchione, MD
Director
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TIFFANY R FARCHIONE
12/01/2025 02:40:53 PM